Oxford Performance Materials, Inc.
$21.8K 20 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Nobelpharma America, LLC
Nobelpharma America, LLC reported $21,734.46 across General Payments, Research, and Ownership to 239 physicians and teaching hospitals across 239 transactions.
- $21.7K Below-median payer
- All-tracks total
- 239 Above-median volume
- Transactions
- 239 Above-median reach
- Recipients
- −$4.8K
- General Payments vs PY2023
Nobelpharma America, LLC reported $21,734.46 across all CMS Open Payments tracks (General + Research + Ownership) to 239 physicians and teaching hospitals in Program Year 2024 - ranking #1525 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $21,734.46, averaging $90.94 per recipient.
How Nobelpharma America, LLC's $21.7K all-tracks total breaks down
Nobelpharma America, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
10/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nobelpharma-america-llc Nobelpharma America, LLC
$21.7K · #1525/1,925 · 0.0% industry · PY2024
- TOT $21.7K
- RANK #1525
- SHARE 0.0%
- TXN 239
- RCP 239
- CAT 3
- GEN $21.7K
- ΔGEN −$4.8K
- TOP1 5.9%
- PY 2024
Volume peers
Nearest volume peer: Oxford Performance Materials, Inc. ($21.8K)
Nobelpharma America, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Nobelpharma America, LLC's CMS-reported General Payments decreased by $4.8K (−18.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOBELPHARMA AMERICA, LLCPY2023: NOBELPHARMA AMERICA, LLCPY2024: NOBELPHARMA AMERICA, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $26,519.51
- PY2024
- $21,734.46
What the Data Shows for Nobelpharma America, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Nobelpharma America, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $15.7K, accounting for 72.0% of this company's General Payments and 27 transactions.
General Payment Breakdown by Type
Nobelpharma America, LLC made 3 types of general payments. "Honoraria" is the largest category at $15.7K, 72.0% of General Payments.
How Nobelpharma America, LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $15.7K | 27 | 72.0% |
| Food and Beverage | $5.9K | 180 | 27.3% |
| Gift | $159.01 | 32 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,450.00 (29.7%) of $21,734.46 in this company's General Payments records across 157 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Nobelpharma America, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Ryan Gill
$1,290.00 across 1 reported transactions
- 2
Elizabeth Thiele
$1,290.00 across 1 reported transactions
- 3
Lawrence Mort
$1,290.00 across 1 reported transactions
- 4
Jamie Wheless
$1,290.00 across 1 reported transactions
- 5
Debopam Samanta
$1,290.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Nobelpharma America, LLC's spend rank (#1525 of 1,925, bottom 21% by spend) and concentration rank (#1,485 of 1,838, bottom 19% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- American Medical & Dental Supplies,Inc. : $49.7K total payments, HHI 276
- Fidia Pharma USA Inc. : $55.5K total payments, HHI 276
- Oak Med, Inc. : $9.5K total payments, HHI 275
- Ortho Dermatologics, a division of Bausch Health US, LLC : $999.3K total payments, HHI 275
- Nalu Medical, Inc. : $823.0K total payments, HHI 275
- Urgo Medical North America, LLC : $258.8K total payments, HHI 274
- Nobelpharma America, LLC (this company) : $21.7K total payments, HHI 272
- Legend Biotech USA Inc. : $189.2K total payments, HHI 272
- Scilex Pharmaceuticals Inc. : $677.6K total payments, HHI 272
- Applied Medical Resources Corporation : $1.8M total payments, HHI 271
- Enduromed, Llc : $26.2K total payments, HHI 271
- Essential Dental Systems Incorporated : $2.7K total payments, HHI 269
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Nobelpharma America, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nobelpharma America, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Nobelpharma America, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Hospira, Inc.
$21.6K 1,203 recipients
Compare payment profiles
Nutech Spine, Inc.
$22.0K 41 recipients
Compare payment profiles
DENTSPLY Canada Ltd
$22.0K 96 recipients
Compare payment profiles
ABC Home Medical Supply, Inc.
$21.4K 996 recipients
Compare payment profiles
Teikoku Pharma USA, Inc.
$21.4K 23 recipients
Compare payment profiles
Put this to use
Nobelpharma America, LLC ranks #1525 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Nobelpharma America, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.